Blog

Vectibix Fails in Treating Metastatic Colon Cancer

At the recent Gastrointestinal Cancers Symposium Meeting, researchers reported that patients who received panitumumab (Vectibix) plus FOLFOX or FOLFIRI actually had a faster progression of metastatic colorectal cancer and were more likely to experience severe toxicities.

Those randomized to panitumumab plus oxaliplatin and bevacizumab (Avastin) had a mean progression-free survival of 9.5 months compared with 11 months in the oxaliplatin/bevacizumab arm 

 

Panitumumab, a fully human monoclonal antibody that targets EGFr, is approved for monotherapy for chemotherapy-refractory metastatic colorectal cancer.